/

Delcath Systems, Inc.

DCTH US

DCTH USDelcath Systems, Inc.

United States Composite

5.30

USD

+0.04

(+0.76%)

-3.61EPS Dil.

-1.47P/E

104.35MMarket Cap

Next Earnings

November 13

Dividend Date

December 24

Held by Insiders

2.27%

Held by Institutions

36.88%

Short % of Float

3.54%

YTD Yield

-38.92%

3Y Yield

-70.78%

5Y Yield

-95.68%

Capital Structure

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

ST Debt

LT Borrowings

LT Finance Leases

- -

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

Market Capitalization

Working Capital

FRC

•

in mil. unless spec.

Mar'23

Jun'23

Sep'23

Total Current Assets

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

8.33%

-25.00%

Net Income, GAAP

-17.95%

-21.38%

-42.31%

Free Cash Flow

2.64%

-11.66%

-8.70%

Total Cash Common Dividend

- -

Total Equity

-255.32%

-440.42%

-150.00%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-1.04

-0.96

-0.94

-0.68

-3.59

2022

-1.00

-1.18

-0.92

-1.03

-4.12

2023

-0.77

-0.58

-1.14

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Gerard J. Michel MBA, MS
Full Time Employees: 52
Sector: Healthcare
Industry: Medical Devices
Address: 1633 Broadway New York NY United States 10019
CIK: 0000872912
Website: www.delcath.com
Business: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Company Description

CEO: Mr. Gerard J. Michel MBA, MS
Full Time Employees: 52
Sector: Healthcare
Industry: Medical Devices
Address: 1633 Broadway New York NY United States 10019
CIK: 0000872912
Website: www.delcath.com
Business: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.